|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn969642985 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
170121s2016 xx o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d N$T
|d YDX
|d OCLCF
|d AGLDB
|d OCLCQ
|d OCLCO
|d D6H
|d VTS
|d STF
|d OCLCQ
|d AJS
|d OCLCO
|d OCLCQ
|
| 066 |
|
|
|c (S
|
| 019 |
|
|
|a 961813824
|a 1264822671
|
| 020 |
|
|
|a 9781681081557
|q (electronic bk.)
|
| 020 |
|
|
|a 1681081555
|q (electronic bk.)
|
| 029 |
1 |
|
|a DEBSZ
|b 493180729
|
| 035 |
|
|
|a (OCoLC)969642985
|z (OCoLC)961813824
|z (OCoLC)1264822671
|
| 050 |
|
4 |
|a RC271.N46
|b A585 2016eb
|
| 072 |
|
7 |
|a MED
|x 075000
|2 bisacsh
|
| 072 |
|
7 |
|a SCI
|x 036000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 612.13
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Anti-angiogenesis drug discovery and development.
|n Volume 3 /
|c editors: Atta-ur-Rahmna, M. Iqbal Coudhary.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (252 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Anti-Angiogenesis Drug Discovery and Development ;
|v v. 3
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|6 880-01
|a PREFACE ; List of Contributors ; Beta-Blocker Therapy for Retinopathy of Prematurity ; 1. WHAT IS ALREADY KNOWN ON THIS TOPIC; 2. WHAT THIS CHAPTER ADDS; 3. INTRODUCTION; 4. FEASIBILITY AND EFFECTIVENESS OF ANTI-ANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY ; Oral Propranolol for Premature Infants with ROP; 4.2. Propranolol Safety and Future in Premature Infants with ROP; 4.3. Ongoing Trials of Propranolol for ROP; 5. FUTURE RESEARCH; ABBREVIATIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES.
|
| 505 |
8 |
|
|a 6.5. KTS Cyclic Peptides Increase Survival of Mice with Melanoma TumorsCONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Current Status of Anti-Angiogenic Therapy in the Clinical Management of Lung Cancer ; 1. ANGIOGENESIS IN THE PATHOGENESIS OF LUNG CANCER; 2. MONOCLONAL ANTIBODIES AS ANTI-ANGIOGENIC THERAPY; 2.1. Bevacizumab in Combination with Platinum-Based Chemotherapy for the First-Line Therapy of NSCLC; 2.2. Other Intravenous Anti-Angiogenic Compounds in First-Line Therapy for NSCLC; 2.3. The Role of Anti-Angiogenic Therapy Upon Disease Progression.
|
| 505 |
8 |
|
|a 2.3a. Bevacizumab2.3b. Ramucirumab; 2.3c. Aflibercept; 2.4. Bevacizumab in Adjuvant, Locally Advanced, or Neoadjuvant Treatment of Advanced NSCLC; 3. SMALL MOLECULE ORAL ANTI-ANGIOGENIC COMPOUNDS IN THE FIRST-LINE THERAPY OF NSCLC; 3.1. Inhibition of a Single Angiogenic Pathway Alone; 3.1a. Vandetanib; 3.2a. Cediranib; 3.2b. Sorafenib; 3.2c. Motesanib; 3.2d. Axitinib; 3.2e. Linifanib; 3.2f. Pazopanib; 4. TRIALS OF ORAL ANTI-ANGIOGENIC COMPOUNDS AFTER FAILURE OF FIRST-LINE THERAPY FOR NSCLC; 4.1. Inhibition of Vascular Endothelial Growth Factor Receptor Alone; 4.1a. Vandetanib.
|
| 505 |
8 |
|
|a 4.1b. Cabozantinib4.2a. Nintedanib; 4.2b. Sunitinib; 4.2c. Sorafenib; 4.2d. Linifanib; 4.2e. Cediranib; 5. ANTI-ANGIOGENIC THERAPY IN SCLC; 5.1. Bevacizumab; 5.2. Sunitinib; 5.3. Vandetanib; 5.4. Sorafenib; 5.5. Thalidomide and Other Immunomodulatory Agents; 5.6. Aflibercept; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Angiogenesis in Hepatocellular Carcinoma (HCC) and its Potential Applications in the Development of Anti-HCC Drugs ; 1. INTRODUCTION; 2. ANGIOGENESIS AND ITS REGULATION IN HEPATOCELLULAR CARCINOMA; 2.1. Angiogenesis Factors in Hepatocellular Carcinoma.
|
| 500 |
|
|
|a 2.1.1. VEGF.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Neovascularization inhibitors.
|
| 650 |
|
0 |
|a Neovascularization.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
2 |
|a Angiogenesis Inhibitors
|
| 650 |
|
2 |
|a Neovascularization, Pathologic
|
| 650 |
|
6 |
|a Néovascularisation
|x Inhibiteurs.
|
| 650 |
|
6 |
|a Néovascularisation.
|
| 650 |
|
6 |
|a Médicaments
|x Développement.
|
| 650 |
|
7 |
|a MEDICAL
|x Physiology.
|2 bisacsh
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Neovascularization.
|2 fast
|0 (OCoLC)fst01035916
|
| 650 |
|
7 |
|a Neovascularization inhibitors.
|2 fast
|0 (OCoLC)fst01035918
|
| 700 |
1 |
|
|a Atta-ur-Rahman.
|
| 700 |
1 |
|
|a Choudhary, M. Iqbal.
|
| 776 |
0 |
8 |
|i Print version:
|a Atta-ur-Rahman.
|t Anti-Angiogenesis Drug Discovery and Development (Volume 3).
|d Sharjah : Bentham Science Publishers, ©2016
|z 9781681081564
|
| 830 |
|
0 |
|a Anti-Angiogenesis Drug Discovery and Development.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511898
|z Texto completo
|
| 880 |
8 |
|
|6 505-01/(S
|a Disintegrin-Based, Synthetic Cyclic KTS Peptides as Novel Dual Antagonists of α1β1/α2β1 Integrins with Antiangiogenic Activity ANGIOGENESIS; 2. Α1Β1 AND Α2Β1 INTEGRINS ARE TARGETS IN ANGIOGENESIS; 3. ANTIANGIOGENIC PEPTIDES IN DRUG DEVELOPMENT; 4. COMPUTATIONAL APPROACHES IN ANTIANGIOGENIC PEPTIDE DRUG DISCOVERY; 5. SNAKE VENOMS DISINTEGRINS; 6. KTS PEPTIDES, PARTIAL ANTAGONISTS OF Α1Β1 AND Α2Β1 INTEGRINS; 6.1. Synthesis of KTS Peptides; 6.2. Modeling of KTS Cyclic Peptides in Water; 6.3. Antiangiogenic Activities of KTS Cyclic Peptides; 6.4. Stability and Safety of KTS Cyclic Peptides.
|
| 936 |
|
|
|a BATCHLOAD
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4727878
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1511898
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 13237568
|
| 994 |
|
|
|a 92
|b IZTAP
|
